Filter Results:
(926)
Show Results For
- All HBS Web
(926)
- People (2)
- News (70)
- Research (778)
- Events (1)
- Multimedia (2)
- Faculty Publications (668)
Show Results For
- All HBS Web
(926)
- People (2)
- News (70)
- Research (778)
- Events (1)
- Multimedia (2)
- Faculty Publications (668)
- April 2010
- Teaching Note
Global Talent Management at Novartis (TN)
By: Jordan I. Siegel
Teaching Note for 708486. View Details
- December 2007 (Revised January 2008)
- Teaching Note
Eli Lilly: Developing Cymbalta (TN)
By: Elie Ofek
Teaching Note for 507-044 View Details
- April 1989 (Revised May 1993)
- Case
Novel Combination of Two Drugs (A)
Herzlinger, Regina E. "Novel Combination of Two Drugs (A)." Harvard Business School Case 189-168, April 1989. (Revised May 1993.)
- April 1989 (Revised July 1992)
- Supplement
Technology Transfer: Anti-Inflammatory Drug (C)
Herzlinger, Regina E. "Technology Transfer: Anti-Inflammatory Drug (C)." Harvard Business School Supplement 189-167, April 1989. (Revised July 1992.)
- May 2005
- Supplement
GlaxoSmithKline: Reorganizing Drug Discovery (B)
By: Robert S. Huckman and Eli Strick
Supplements the (A) case. View Details
Keywords: Mergers and Acquisitions; Decisions; Operations; Performance; Research and Development; Restructuring; Organizations; Pharmaceutical Industry
Huckman, Robert S., and Eli Strick. "GlaxoSmithKline: Reorganizing Drug Discovery (B)." Harvard Business School Supplement 605-075, May 2005.
- August 2004 (Revised July 2006)
- Case
PROPECIA TM: Helping Make Hair Loss History
By: Marta Wosinska and Youngme E. Moon
In late 1997, Tom Casola, brand manager for Propecia, debates the best approach to market this breakthrough one-a-day pill for hair loss. This launch would be atypical for a prescription drug because of the key position of the consumer. As a result, the team's... View Details
Keywords: Advertising; Communication Strategy; Customers; Marketing Communications; Marketing Strategy; Product Launch; Product; Performance Effectiveness; Problems and Challenges; Quality; Pharmaceutical Industry
Wosinska, Marta, and Youngme E. Moon. "PROPECIA TM: Helping Make Hair Loss History." Harvard Business School Case 505-035, August 2004. (Revised July 2006.)
- July 2004 (Revised February 2005)
- Teaching Note
Marketing Antidepressants: Prozac and Paxil (TN)
By: Youngme E. Moon
Teaching Note to (9-502-055). View Details
- March 2001 (Revised September 2002)
- Case
Merck Latin America (D): Mexico
By: Michael Beer and James Weber
Examines Merck's change effort in Mexico from the perspective of the local employees. View Details
Keywords: Change Management; Cross-Cultural and Cross-Border Issues; Multinational Firms and Management; Employees; Operations; Perspective; Pharmaceutical Industry; Mexico
Beer, Michael, and James Weber. "Merck Latin America (D): Mexico." Harvard Business School Case 401-032, March 2001. (Revised September 2002.)
- March 2001 (Revised September 2002)
- Case
Merck Latin America (A)
By: Michael Beer and James Weber
Introduces Grey Warner, the vice president of Merck's Latin America region, and his efforts to improve the organizational effectiveness of the region and to introduce a more global business culture and values. Discusses Merck's ethics and values, its Latin American... View Details
Keywords: Organizational Culture; Ethics; Business Processes; Strategic Planning; Change Management; Values and Beliefs; Globalized Firms and Management; Employee Relationship Management; Business Strategy; Government and Politics; Economy; Pharmaceutical Industry; Latin America
Beer, Michael, and James Weber. "Merck Latin America (A)." Harvard Business School Case 401-029, March 2001. (Revised September 2002.)
- February 2000 (Revised June 2003)
- Case
Pepcid AC: Racing to the OTC Market
By: Charles King III, Alvin J. Silk, Ernst R. Berndt and Lisa R. Klein
Pepcid management must decide whether to risk all in a race to be first in the over-the-counter market with a new heartburn remedy. View Details
Keywords: Competitive Advantage; Product Positioning; Markets; Research; Marketing Strategy; Product Development; Decision Choices and Conditions; Pharmaceutical Industry
King, Charles, III, Alvin J. Silk, Ernst R. Berndt, and Lisa R. Klein. "Pepcid AC: Racing to the OTC Market." Harvard Business School Case 500-073, February 2000. (Revised June 2003.)
- June 1999 (Revised October 1999)
- Case
Eli Lilly, 1998 (B): Emerging Global Organization
By: Michael Y. Yoshino and Thomas W. Malnight
Examines major issues faced by Eli Lilly as it evaluates the appropriateness of a focused matrix organization with extensive use of cross-functional teams. View Details
Keywords: Business Model; Geography; Globalized Firms and Management; Growth and Development; Knowledge; Management Teams; Product; Organizations; Pharmaceutical Industry
Yoshino, Michael Y., and Thomas W. Malnight. "Eli Lilly, 1998 (B): Emerging Global Organization." Harvard Business School Case 399-174, June 1999. (Revised October 1999.)
- October 1987 (Revised November 1994)
- Case
Boston Fights Drugs (A): Designing Communications Research
Describes in detail the research mounted by five individuals with a $20,000 budget to combat drug abuse among Boston's school-going population. Using the focus group methodology they discover that most of the current anti-drug advertising is useless. They create their... View Details
Keywords: Budgets and Budgeting; Misleading and Fraudulent Advertising; Communication Intention and Meaning; Brands and Branding; Performance Evaluation; Research and Development; Segmentation; Pharmaceutical Industry; Boston
Rangan, V. Kasturi. "Boston Fights Drugs (A): Designing Communications Research." Harvard Business School Case 588-031, October 1987. (Revised November 1994.)
- September 1983 (Revised October 1984)
- Case
Syntex Laboratories (A)
A consulting project involving a mathematical model of the sales force indicates that Syntex Labs should nearly double the size of their sales force and drastically alter their allocation of sales effort to the product line and physician specialties. The questions are... View Details
Keywords: Organizational Change and Adaptation; Strategic Planning; Salesforce Management; Pharmaceutical Industry
Clarke, Darral G. "Syntex Laboratories (A)." Harvard Business School Case 584-033, September 1983. (Revised October 1984.)
- March 1980 (Revised February 1984)
- Case
Kramer Pharmaceuticals, Inc.
The 12-year career of Mr. Bob Marsh is traced, from recruitment to termination. Data on Kramer's sales management, performance evaluation, compensation, and sales training systems are given. View Details
Newton, Derek A. "Kramer Pharmaceuticals, Inc." Harvard Business School Case 580-125, March 1980. (Revised February 1984.)
- 01 Jan 2008
- News
Jeffrey R. Immelt, MBA 1982
Jeff Immelt’s night table—Railway Age, Aviation Week, Broadcasting & Cable—represents just a few of the industries encompassed by General Electric, the company founded by Thomas Edison where Immelt is entering his ninth year as chairman... View Details
- 01 Aug 2001
- News
Cleveland Global Alumni Conference a Sold-Out Success
& Co., kicked off the first plenary session with a quick overview of factors contributing to the U.S. pharmaceutical industry's success in competing in the global market. Among other ad- vantages, Gilmartin cited the U.S. government's... View Details
- 23 May 2000
- Research & Ideas
Minding the Muse: The Impact of Downsizing on Corporate Creativity
pharmaceutical firms that rely on creativity," she says. "Today's fast-changing global markets place increased pressure on companies of every kind to continuously create new products, services, and competitive strategies if they... View Details
Keywords: by Peter K. Jacobs
- 18 Aug 2017
- Op-Ed
Op-Ed: Courageous Leader Triggers a Moral Revolt of CEOs Against Trump
actions was not without risk for the CEOs and their companies” While many CEOs prefer to stay under the radar and avoid public scrutiny, Ken Frazier led the way with his example. As the chair of PhRMA, the pharmaceutical manufacturers... View Details
Keywords: by Bill George
- 01 Mar 2012
- News
How to Close the Health Gap
real progress has been made over the last decade, thanks in part to funding from organizations such as the Bill & Melinda Gates Foundation and efforts by pharmaceutical companies and governments to make drugs available at little or no... View Details
- 13 Oct 2016
- News
Adding Muscle to the Fight Against Disease
portfolio of programs in parallel.” In an industry where serial entrepreneurship is the norm, Cytokinetics’s approach instead requires “a strategy based on sustainability and durability” that includes forging significant partnerships with... View Details
Keywords: Deborah Blagg